Valuation: Mylan Inc

Market Cap 1.89TCr 1.66TCr 1.54TCr 1.42TCr 2.68TCr 1,81300Cr 2.73TCr 18TCr 7.2TCr 89TCr 7.11TCr 6.96TCr 3,07600Cr P/E 2026 *
69.8x
P/E 2027 * 25.8x
Enterprise Value 3.11TCr 2.73TCr 2.53TCr 2.33TCr 4.4TCr 2,98000Cr 4.49TCr 30TCr 12TCr 1,46300Cr 12TCr 11TCr 5,05400Cr EV / Sales 2026 *
2.11x
EV / Sales 2027 * 1.99x
Free-Float
92.23%
Yield 2026 *
3.13%
Yield 2027 * 3.21%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.12%-1.13%+48.44%+172.96% 1,06000Cr
+0.38%-0.55%+64.46%+62.40% 62TCr
-0.35%-3.09%+28.91%+84.81% 44TCr
-1.75%-0.33%+28.33%+23.58% 33TCr
+0.24%-0.42%+29.19%+47.26% 28TCr
-1.75%-10.57%+18.27%+22.07% 27TCr
+0.67%+1.03%-26.81%-37.96% 22TCr
-1.10%-2.03%+20.86%+57.69% 20TCr
+0.70%+0.91%+16.68%+70.49% 16TCr
Average -0.28%-3.33%+25.37%+55.92% 39.71TCr
Weighted average by Cap. -0.24%-3.10%+35.63%+84.10%

Financials

2026 *2027 *
Net sales 1.48TCr 1.3TCr 1.2TCr 1.1TCr 2.09TCr 1,41400Cr 2.13TCr 14TCr 5.61TCr 69TCr 5.55TCr 5.43TCr 2,39800Cr 1.5TCr 1.32TCr 1.22TCr 1.12TCr 2.13TCr 1,43900Cr 2.17TCr 15TCr 5.71TCr 71TCr 5.65TCr 5.52TCr 2,44100Cr
Net income 1.3Cr 1.14Cr 1.06Cr 97.15L 1.84Cr 124.4Cr 1.87Cr 13Cr 4.94Cr 61Cr 4.88Cr 4.77Cr 210.98Cr 50Cr 44Cr 40Cr 37Cr 70Cr 4.76TCr 72Cr 481.72Cr 188.93Cr 2.34TCr 186.83Cr 182.74Cr 8.08TCr
Net Debt 1.22TCr 1.07TCr 990Cr 910.91Cr 1.72TCr 1,16600Cr 1.76TCr 12TCr 4.63TCr 57TCr 4.58TCr 4.48TCr 1,97800Cr 1.1TCr 967.49Cr 896.07Cr 824.49Cr 1.56TCr 1,05600Cr 1.59TCr 11TCr 4.19TCr 52TCr 4.14TCr 4.05TCr 1,79000Cr
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-